Bortezomib administration examination for high sensitization renal transplantation candidates.

Bortezomib administration examination for high sensitization renal transplantation candidates. - Bortezomib for high sensitized renal transplantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012837

Enrollment

Registered

2014-01-14

Start date

2013-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high sensitized renal transplantation candidates

Interventions

1.3 mg/m2 bortezomib is administrated by subcutaneous injection after transplant on the POD1, 4, 8, 11.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: positive crossmatch high level of DSA

Exclusion criteria

Exclusion criteria: myelosuppression inflammatory lung disease

Design outcomes

Primary

Measure	Time frame
I perform kidney biopsy after transplant approximately three months later and confirm it pathologically	—

Countries

Japan

Contacts

Public ContactToshiro Nakatsuka

Ehime University Medical department research partnership division

uroyuukictb12@yahoo.co.jp089-960-5172

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026